Evidence map›Paper›PMID 36941056›Full record

ArticleLife science alliance2023

Potency assessment of IFNγ-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects.

Rubén Gil-Bescós, Ainhoa Ostiz, Saioa Zalba, Ibai Tamayo, Eva Bandrés, Elvira Rojas-de-Miguel, Margarita Redondo, Amaya Zabalza, Natalia Ramírez

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rubén Gil-BescósOncohematology Research Group, Navarrabiomed, University Hospital of Navarra, Public University of Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.ORCID https://orcid.org/0000-0002-6824-6862
Ainhoa OstizOncohematology Research Group, Navarrabiomed, University Hospital of Navarra, Public University of Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.ORCID https://orcid.org/0000-0002-9006-8345
Saioa ZalbaHematology and Hemotherapy Department, University Hospital of Navarra, IdiSNA, Pamplona, Spain.ORCID https://orcid.org/0000-0003-3201-1882
Ibai TamayoUnit of Methodology, Navarrabiomed, University Hospital of Navarra, Public University of Navarra, IdiSNA, Pamplona, Spain.ORCID https://orcid.org/0000-0003-2860-3359
Eva BandrésImmunology Service, University Hospital of Navarra, IdiSNA, Pamplona, Spain.ORCID https://orcid.org/0000-0002-9497-5356
Elvira Rojas-de-MiguelOncohematology Research Group, Navarrabiomed, University Hospital of Navarra, Public University of Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.ORCID https://orcid.org/0000-0002-3085-8935
Margarita RedondoHematology and Hemotherapy Department, University Hospital of Navarra, IdiSNA, Pamplona, Spain.ORCID https://orcid.org/0000-0002-0868-6663
Amaya ZabalzaOncohematology Research Group, Navarrabiomed, University Hospital of Navarra, Public University of Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain natalia.ramirez.huerto@navarra.es amaya.zabalza.sanmartin@navarra.es.ORCID https://orcid.org/0000-0002-3160-2683
Natalia RamírezOncohematology Research Group, Navarrabiomed, University Hospital of Navarra, Public University of Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain natalia.ramirez.huerto@navarra.es amaya.zabalza.sanmartin@navarra.es.ORCID https://orcid.org/0000-0003-3669-1053
Navarrabiomed · ESUniversidad de Navarra · ESRed de Investigación en Actividades Preventivas y Promoción de la Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of new therapies for COVID-19 high-risk patients remains necessary to prevent additional deaths. Here, we studied the phenotypical and functional characteristics of IFN-γ producing-SARS-CoV-2-specific T cells (SC2-STs), obtained from 12 COVID-19 convalescent donors, to determine their potency as an off-the-shelf T cell therapy product. We found that these cells present mainly an effector memory phenotype, characterized by the basal expression of cytotoxicity and activation markers, including granzyme B, perforin, CD38, and PD-1. We demonstrated that SC2-STs could be expanded and isolated in vitro, and they exhibited peptide-specific cytolytic and proliferative responses after antigenic re-challenge. Collectively, these data demonstrate that SC2-STs can be a suitable candidate for the manufacture of a T cell therapy product aimed to treat severe COVID-19.

Indexed as

COVID-19HumansInterferon-gammaPeptidesSARS-CoV-2T-LymphocytesInterferon-gammaPeptides

Identifiers

PMID36941056
PMCPMC10027900
OpenAlexW4327910367

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read104
identifiers read5
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.